Sumanta Pal provides an overview of the phase 2 SWOG 1500 study pitting the MET inhibitors cabozantinib, crizotinib, and savolitinib against sunitinib for the treatment of metastatic papillary renal cell carcinoma (3:49).
25-02-2021 | ASCO GU 2021 | Conference coverage | Video